EP1782805A1 - Composition d'accélération d'absorption de calcium - Google Patents

Composition d'accélération d'absorption de calcium Download PDF

Info

Publication number
EP1782805A1
EP1782805A1 EP05768493A EP05768493A EP1782805A1 EP 1782805 A1 EP1782805 A1 EP 1782805A1 EP 05768493 A EP05768493 A EP 05768493A EP 05768493 A EP05768493 A EP 05768493A EP 1782805 A1 EP1782805 A1 EP 1782805A1
Authority
EP
European Patent Office
Prior art keywords
calcium
acid
group
arabonic acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05768493A
Other languages
German (de)
English (en)
Other versions
EP1782805A4 (fr
Inventor
Kazuko Godo Shusei Co. Ltd. SANAI
Yuko Godo Shusei Co. Ltd. TANAKA
Shigenori Godo Shusei Co. Ltd. NEGISHI
Kenji Seri
Hironori Godo Shusei Co. Ltd. SASAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Godo Shusei KK
Original Assignee
Godo Shusei KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2004229793A external-priority patent/JP2006045137A/ja
Application filed by Godo Shusei KK filed Critical Godo Shusei KK
Publication of EP1782805A1 publication Critical patent/EP1782805A1/fr
Publication of EP1782805A4 publication Critical patent/EP1782805A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the food additive of the present invention is prepared for use by formulating L-arabonic acid, a salt thereof or L-arabonolactone directly, or appropriately in combination with various anticaking agents, excipients or media, into a powder, a granule, a tablet, a liquid such as an aqueous solution, according to a standard method.
  • mice 11-weeks old male ICR mice were used after overnight fasting. During the test period, the mice were given deionized water only. The mice were divided into 8 groups (Groups I to VIII, 5 animals in each group), and all of the groups were orally administered with 5 mmol/kg of calcium carbonate, which corresponds to a dose of 200 mg of calcium/kg.
  • Group I was administered with calcium carbonate only
  • Groups II to V were orally administered with calcium carbonate and L-arabonic acid simultaneously
  • Groups VI to VIII were orally administered with calcium carbonate and D-gluconic acid simultaneously.
  • the conditions for the HPLC analysis were as follows. Column: ICSepICE-ION-300 (Transgenomic, Inc.), 0.78 cm in internal diameter x 30 cm in length, column temperature: 70°C, eluent: 0.0085 N aqueous sulfuric acid solution, detector: differential refractometer detector (Showa Denko K. K., RI SE-61), flow rate: 0.4 mL/min, and retention time for eluted L-arabonic acid: approximately 17.5 min.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05768493A 2004-08-05 2005-08-04 Composition d'accélération d'absorption de calcium Withdrawn EP1782805A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004229793A JP2006045137A (ja) 2004-08-05 2004-08-05 骨粗鬆症の予防および治療用組成物
JP2004229792 2004-08-05
PCT/JP2005/014312 WO2006013929A1 (fr) 2004-08-05 2005-08-04 Composition d’accélération d’absorption de calcium

Publications (2)

Publication Number Publication Date
EP1782805A1 true EP1782805A1 (fr) 2007-05-09
EP1782805A4 EP1782805A4 (fr) 2007-08-08

Family

ID=35787208

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05768493A Withdrawn EP1782805A4 (fr) 2004-08-05 2005-08-04 Composition d'accélération d'absorption de calcium

Country Status (5)

Country Link
US (1) US20070293443A1 (fr)
EP (1) EP1782805A4 (fr)
KR (1) KR20070039581A (fr)
CA (1) CA2576022A1 (fr)
WO (1) WO2006013929A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635800A1 (fr) * 2006-01-31 2007-08-09 Godo Shusei Co., Ltd. Prevention/traitement de la calculose urinaire
JP5122766B2 (ja) 2006-06-20 2013-01-16 ユニチカ株式会社 エコール産生促進組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438883A (en) * 1946-04-02 1948-03-30 Hoffmann La Roche Process of making ribonolactone
GB633967A (en) * 1945-03-30 1949-12-30 Roche Products Ltd A process for the manufacture of calcium salts of phosphorylated arabonic acid and derivatives thereof
EP0060445A1 (fr) * 1981-03-12 1982-09-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de résolution de racémates, et lactonesters employés dans ce procédé
US6077872A (en) * 1998-07-08 2000-06-20 Beijing Jueng Asia Pacific Life Scientific Research Center Use of calcium L-threonate in preventing, inhibiting and curing osteoporosis and rickets
US20020169210A1 (en) * 2001-03-07 2002-11-14 Kai Yu Method for treating or preventing bone fracture

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5112966A (en) * 1974-07-23 1976-01-31 Nippon Suisan Kaisha Ltd Gyonikuhamu sooseejino seizoho
FR2446806A1 (fr) * 1979-01-22 1980-08-14 Solvay Procede pour la fabrication d'acides aldoniques par voie enzymatique
JPS5635970A (en) * 1979-09-03 1981-04-08 Kaneshichi Kk Production of fish-meat kneaded product with acidic taste
JPS59216570A (ja) * 1983-05-26 1984-12-06 Kibun Kk 魚肉練製品入りサラダの製造方法
JPH01132788A (ja) * 1987-11-18 1989-05-25 Mita Ind Co Ltd 脱脂方法およびその装置
US6352713B1 (en) * 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
JP2001245657A (ja) * 1999-12-27 2001-09-11 Takehara Kagaku Kogyo Kk アルドン酸を産生する新規菌体およびその酵素
JP2002220398A (ja) * 2001-01-26 2002-08-09 Mitsubishi Chemicals Corp リボースの製造方法
JP2001327298A (ja) * 2001-05-22 2001-11-27 National Food Research Institute 酸性糖質の製造方法
JP2005021153A (ja) * 2002-12-26 2005-01-27 Toyo Suisan Kaisha Ltd アクリルアミドを低減化し得る加熱調理食品の製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB633967A (en) * 1945-03-30 1949-12-30 Roche Products Ltd A process for the manufacture of calcium salts of phosphorylated arabonic acid and derivatives thereof
US2438883A (en) * 1946-04-02 1948-03-30 Hoffmann La Roche Process of making ribonolactone
EP0060445A1 (fr) * 1981-03-12 1982-09-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de résolution de racémates, et lactonesters employés dans ce procédé
US6077872A (en) * 1998-07-08 2000-06-20 Beijing Jueng Asia Pacific Life Scientific Research Center Use of calcium L-threonate in preventing, inhibiting and curing osteoporosis and rickets
US20020169210A1 (en) * 2001-03-07 2002-11-14 Kai Yu Method for treating or preventing bone fracture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006013929A1 *

Also Published As

Publication number Publication date
US20070293443A1 (en) 2007-12-20
CA2576022A1 (fr) 2006-02-09
EP1782805A4 (fr) 2007-08-08
WO2006013929A1 (fr) 2006-02-09
KR20070039581A (ko) 2007-04-12

Similar Documents

Publication Publication Date Title
EP0667107B1 (fr) Promoteur de croissance de bifidus
EP2156751B1 (fr) Edulcorant inédit au goût de sucre, son procédé de fabrication et son utilisation
US9109266B2 (en) Process of producing sugar composition comprising D-psicose and D-allose via strong alkaline isomerization of D-glucose/D-fructose or alkaline pre-treatment of D-glucose/D-fructose followed by isomerization in the presence of a basic ion exchange resin
US4786510A (en) Calcium-iron mineral supplements
KR101007790B1 (ko) 트레할로오스 또는 말티톨과 금속 이온 화합물과의 회합물(會合物)
JP5270144B2 (ja) マルトビオン酸、その塩又はマルトビオノデルタラクトン含有組成物の用途
US20030207942A1 (en) Hydroxycitric acid salt composition and method of making
JP4931352B2 (ja) 鉄補給剤及びその利用
EP1452097B1 (fr) Complexe mineral comprenant de l'acide lactobionique et méthode d'utilisation pour l'enrichissement en mineraux de produits alimentaires
WO2005067970A1 (fr) Complement de fer et son utilisation
JP2003000195A (ja) 水分散性又は水溶解性のイチョウ葉抽出物組成物
EP0343703A2 (fr) Suppléments minéraux avec alcool de sucre
JP4401659B2 (ja) インスリン分泌促進剤
EP1782805A1 (fr) Composition d'accélération d'absorption de calcium
JP2008143811A (ja) 脂質代謝促進組成物
WO2004089964A1 (fr) Agent regulateur de lipides et son utilisation
JP5586713B2 (ja) ミネラル可溶化安定剤
JP5222299B2 (ja) 脂肪吸収抑制組成物
JPH06205653A (ja) ラクチュロースオリゴ糖を有効成分とするミネラル吸収促進剤
JP5695098B2 (ja) 脂質代謝改善剤
JP5628355B2 (ja) ミネラル吸収促進剤及び易吸収性カルシウム剤
US20090155391A1 (en) Hydroxycitric acid salt composition and method of use for reducing body weight
JPH0881372A (ja) 赤血球数の減少に起因する医学的症状の予防及び改善剤
KR20220139746A (ko) 떫은 맛이 저감되어 전반적인 관능이 향상된 유청분리단백질 및 전해질 함유 기능성 음료 및 그 조성물
KR100225533B1 (ko) 비피도박테리움 증식 촉진제(Biridobacterium growth promotr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070705

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/191 20060101AFI20060706BHEP

Ipc: C07D 307/33 20060101ALI20070629BHEP

Ipc: A61P 3/14 20060101ALI20070629BHEP

Ipc: A23L 1/304 20060101ALI20070629BHEP

Ipc: A23L 1/30 20060101ALI20070629BHEP

Ipc: A61K 31/365 20060101ALI20070629BHEP

Ipc: A61P 19/10 20060101ALI20070629BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100406